Peptide Therapy for Women: Special Considerations

Peptide therapy for women requires extra care because pregnancy potential, contraception, menstrual cycles, perimenopause and conditions like iron deficiency or thyroid disease all change the risk-benefit calculation. Most investigational peptides were studied mainly in animals, often male animals, so data in women are especially thin. A few peptide-based drugs are FDA-approved with clear labeling; those are the right place to start.

Many of the women I see are thoughtful, well-read and frustrated: they have symptoms that were dismissed, and they want options. I take that seriously. Taking it seriously also means being clear about what peptides can and cannot offer, and what needs to be checked first.

Why Peptide Therapy for Women Needs Its Own Conversation

Women are underrepresented in the evidence

Much of the peptide literature comes from rodent studies, and many of those used male animals. Human trials of investigational peptides are small. That means we often do not know whether effects, side effects or optimal approaches differ by sex, menstrual phase or menopausal status.

Hormones are a moving target

A woman's hormonal environment changes across the cycle, during pregnancy and postpartum, and through perimenopause and menopause. Symptoms like fatigue, poor sleep, weight change, low libido and brain fog have many possible causes in each of these phases. For more on that, see hormone optimization for women over 40.

Pregnancy, Breastfeeding and Contraception

This is the first and most important filter.

• Investigational peptides have no adequate safety data in pregnancy or breastfeeding. I do not consider them in women who are pregnant, breastfeeding, or trying to conceive.
• FDA-approved GLP-1 medications have specific labeled guidance. Semaglutide labeling, for example, advises stopping it at least two months before a planned pregnancy.
• Contraception interactions: tirzepatide can reduce absorption of oral contraceptives. Its labeling advises switching to a non-oral method or adding a barrier method for a period after starting and after each dose increase.
• Fertility effects of weight loss: as weight and insulin sensitivity improve, ovulation can resume in women who were not ovulating regularly. Unexpected pregnancies are a real consideration.

FDA-Approved Options Relevant to Women

Bremelanotide (PT-141)

PT-141, sold as Vyleesi, is FDA-approved for premenopausal women with acquired, generalized hypoactive sexual desire disorder, a specific diagnosis of distressing low desire not explained by another medical condition, relationship problem or medication. It acts on melanocortin receptors in the brain. Common side effects include nausea, flushing and headache; it can transiently raise blood pressure and is not appropriate for people with uncontrolled hypertension or known cardiovascular disease. I review it in detail in PT-141 (bremelanotide): the FDA-approved sexual health peptide.

GLP-1 and dual agonists

Semaglutide and tirzepatide are FDA-approved for type 2 diabetes and chronic weight management (specific products for each). In women, I pay particular attention to the contraception and pregnancy points above, adequate protein intake and resistance training to protect muscle and bone, and gallbladder symptoms.

Investigational Peptides: Women-Specific Cautions

When women ask about investigational compounds, these are the issues I raise:

• Growth hormone secretagogues can cause fluid retention and affect insulin sensitivity, and their use is generally avoided in people with a history of hormone-sensitive or other cancers.
• Melanotan II increases skin pigmentation and can change the appearance of moles, which complicates skin-cancer surveillance; it is not FDA-approved.
• Kisspeptin is an active area of reproductive research, including in fertility treatment settings, but it is not FDA-approved and remains restricted for compounding.
• Breast cancer history: compounds that act on growth pathways or telomerase raise theoretical concerns. These deserve a discussion with your oncologist.
• Regulatory status: many popular peptides are not FDA-approved, and several remain under FDA review for compounding as of this writing. Check current FDA guidance.

Dosing for investigational compounds is individualized and discussed only after evaluation and labs. I do not publish protocols. More on why in why physician supervision matters before considering peptides.

Labs I Prioritize for Women

Before any optimization discussion, I want a clear picture:

• CBC and ferritin, because iron deficiency is common and causes fatigue, hair shedding and poor exercise tolerance
• TSH with free T4 as indicated
• Metabolic panel, lipids, HbA1c
• Vitamin D and B12 when relevant
• Hormone testing chosen for the life stage and symptoms; for example, cycle-timed testing in some situations, while in perimenopause symptoms often guide decisions more than single hormone values
• Bone health assessment where age and risk factors warrant

The Bottom Line

At Laeeq M.D., I approach peptide therapy for women with curiosity and caution in equal measure. Some peptide-based medicines have strong evidence and clear labeling. Many others are promising but unproven, and the unknowns are greater for women because women have been studied less. A careful evaluation protects you from both overtreatment and missed diagnoses.

Sources

• VYLEESI (bremelanotide injection) Prescribing Information — U.S. Food and Drug Administration, 2019. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf
• Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks — U.S. Food and Drug Administration, 2026. https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks

Book a Consultation

If you are a woman considering peptides, weight-loss medications or hormone support, start with an evaluation that takes your full history into account. You can book a consultation for a 60-minute visit with Dr. Laeeq, virtually or in Reston, VA, for patients in Virginia, Maryland, Florida, Texas, California, Pennsylvania and Tennessee.

This article is for educational purposes and is not medical advice. Discuss any treatment with a licensed physician who knows your history.